Randomized trial of XXXX for @entity2835 .

@entity1 @entity2835 @entity82 @entity648 @entity5805 @entity492 @entity236
Twenty-four @entity1 with @entity2835 were entered into a prospective, randomized trial of @entity5805 therapy. Thirteen @entity1 received @entity5805 (0.5-4 mg/day) and 11 @entity1 received no therapy; all have been followed for 2-6 yr (mean, 4.1 yr). Two control but no treated @entity1 died. Average serum @entity648 , serum @entity492 aminotransferase activities, and albumin levels improved or remained unchanged in treated @entity1 but worsened in controls. Serum alkaline phosphatase levels did not change in either group. Immunoglobulin M levels decreased and became normal in all treated @entity1 but in only 3 control @entity1 . Liver biopsy histology revealed an improvement in inflammatory cell infiltrate in treated @entity1 in comparison with controls, but no significant change in degree of @entity82 or the histologic stage of disease. Side effects of therapy included @entity236 necessitating discontinuation of the drug in 4 @entity1 . These findings indicate that @entity5805 therapy may retard the progression of @entity2835 . Whether such therapy will ultimately decrease morbidity and improve survival in this disease can only be demonstrated by large-scale, placebo-controlled trials.
